Published in Biochem Pharmacol on October 11, 2007
Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. Ann Surg Oncol (2009) 1.80
Mechanisms of glioma-associated neovascularization. Am J Pathol (2012) 1.39
Determination of breast cancer response to bevacizumab therapy using contrast-enhanced ultrasound and artificial neural networks. J Ultrasound Med (2010) 1.11
Hyperpolarized (13)C spectroscopy detects early changes in tumor vasculature and metabolism after VEGF neutralization. Cancer Res (2012) 1.07
Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality. EMBO Mol Med (2015) 1.07
Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models. Clin Cancer Res (2010) 0.98
A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study. J Gastrointest Cancer (2012) 0.88
Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: a molecular imaging study. Transl Oncol (2010) 0.87
Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer. BMC Cancer (2009) 0.87
Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of experimental data. Biol Direct (2016) 0.84
Role of apoptosis in colon cancer biology, therapy, and prevention. Curr Colorectal Cancer Rep (2013) 0.83
A novel angiogenesis inhibitor bevacizumab induces apoptosis in the rat endometriosis model. Balkan J Med Genet (2015) 0.82
Tumor cell response to bevacizumab single agent therapy in vitro. Cancer Cell Int (2013) 0.82
Modeling efficacy of bevacizumab treatment for metastatic colon cancer. J Cancer (2013) 0.81
Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer. Mol Cancer Ther (2012) 0.79
Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial. Br J Cancer (2015) 0.78
Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging Agents. Clin Cancer Res (2015) 0.77
Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways. Oncotarget (2015) 0.77
High serum levels of interleukin-6 in patients with advanced or metastatic colorectal cancer: the effect on the outcome and the response to chemotherapy plus bevacizumab. Surg Today (2016) 0.77
Efficacy of suicide gene therapy in hypoxic rat 9L glioma cells. J Neurooncol (2008) 0.76
Repurposing Drugs in Oncology (ReDO)-nitroglycerin as an anti-cancer agent. Ecancermedicalscience (2015) 0.75
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods (1983) 114.35
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
The biology of VEGF and its receptors. Nat Med (2003) 32.13
Angiogenesis in cancer and other diseases. Nature (2000) 28.28
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 23.44
Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer (2002) 20.51
Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature (1998) 11.61
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol (2004) 10.55
Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med (2001) 10.37
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature (1996) 10.14
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov (2004) 9.96
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res (1996) 6.62
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res (2000) 6.42
The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer (2004) 6.32
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest (2000) 5.52
HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med (2002) 4.13
The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell (2003) 3.89
Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest (1995) 3.52
Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol (1994) 3.30
Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell (2004) 3.28
High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A (1992) 3.22
The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res (1999) 2.91
Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci U S A (1997) 2.86
Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res (2002) 2.69
Prevention of hypoxia-induced cell death by Bcl-2 and Bcl-xL. Nature (1995) 2.40
Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther (2004) 2.32
The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol Ther (1991) 2.06
Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res (2000) 2.02
Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res (2004) 1.96
Hypoxia inducible factor-1alpha as a cancer drug target. Mol Cancer Ther (2004) 1.92
Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol (1998) 1.85
Induction of apoptosis as well as necrosis by hypoxia and predominant prevention of apoptosis by Bcl-2 and Bcl-XL. Cancer Res (1996) 1.84
Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol (2001) 1.76
Tumor angiogenesis and interstitial hypertension. Cancer Res (1996) 1.63
Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein. Cancer Res (1983) 1.53
Microvascular studies on the origins of perfusion-limited hypoxia. Br J Cancer Suppl (1996) 1.38
Response of tumour cells to hypoxia: role of p53 and NFkB. Mol Pathol (1998) 1.37
Tumor hypoxia and gene expression--implications for malignant progression and therapy. Acta Oncol (1998) 1.23
Changes of angiogenesis and tumor cell apoptosis during colorectal carcinogenesis. Clin Cancer Res (1999) 1.10
Targeting hypoxia tolerance in cancer. Drug Resist Updat (2004) 1.07
Glutathione S-transferases in nitrogen mustard-resistant and -sensitive cell lines. Mol Pharmacol (1987) 1.06
Apoptosis in human adenocarcinoma HT29 cells induced by exposure to hypoxia. J Natl Cancer Inst (1995) 1.02
Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer. Br J Cancer (1999) 0.96
In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo. Br J Cancer (2005) 0.93
Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo. Cancer Res (1989) 0.88
p53 promotes selection for Fas-mediated apoptotic resistance. Cancer Res (2000) 0.87
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol (2007) 11.77
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 7.95
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77
Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol (2008) 5.31
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol (2012) 4.19
Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol (2006) 3.59
Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study. J Clin Oncol (2002) 3.25
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol (2007) 2.92
Computerized image-based detection and grading of lymphocytic infiltration in HER2+ breast cancer histopathology. IEEE Trans Biomed Eng (2009) 2.56
Gene expression patterns in ovarian carcinomas. Mol Biol Cell (2003) 2.55
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol (2010) 2.43
Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res (2002) 2.25
Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol (2010) 2.10
Automated detection of prostatic adenocarcinoma from high-resolution ex vivo MRI. IEEE Trans Med Imaging (2005) 2.08
Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res (2002) 2.05
High-throughput detection of prostate cancer in histological sections using probabilistic pairwise Markov models. Med Image Anal (2010) 2.04
Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res (2011) 2.03
Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer. Clin Colorectal Cancer (2002) 2.02
HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype. J Clin Invest (2010) 2.00
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res (2008) 1.99
Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol (2003) 1.88
Activated STAT3 is a mediator and biomarker of VEGF endothelial activation. Cancer Biol Ther (2008) 1.77
APOBEC3 proteins expressed in mammary epithelial cells are packaged into retroviruses and can restrict transmission of milk-borne virions. Cell Host Microbe (2010) 1.67
Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Am J Pathol (2006) 1.66
Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans. Cancer Biol Ther (2008) 1.65
A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. Cancer Res (2009) 1.64
Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias. J Clin Oncol (2007) 1.64
High rate of consent to bank biologic samples for future research: the Eastern Cooperative Oncology Group experience. J Natl Cancer Inst (2002) 1.60
Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther (2008) 1.58
Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am J Pathol (2003) 1.52
Cascaded discrimination of normal, abnormal, and confounder classes in histopathology: Gleason grading of prostate cancer. BMC Bioinformatics (2012) 1.42
High throughput analysis of breast cancer specimens on the grid. Med Image Comput Comput Assist Interv (2007) 1.40
Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases. Clin Cancer Res (2009) 1.30
Determining histology-MRI slice correspondences for defining MRI-based disease signatures of prostate cancer. Comput Med Imaging Graph (2011) 1.28
Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol (2006) 1.22
Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab. Clin Cancer Res (2012) 1.21
Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapy. Clin Cancer Res (2013) 1.21
ATF4-dependent induction of heme oxygenase 1 prevents anoikis and promotes metastasis. J Clin Invest (2015) 1.17
Downregulation of Rap1GAP contributes to Ras transformation. Mol Cell Biol (2007) 1.16
Characterization CSMD1 in a large set of primary lung, head and neck, breast and skin cancer tissues. Cancer Biol Ther (2009) 1.14
Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin Cancer Res (2005) 1.12
Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol (2010) 1.12
Role of Jun and Jun kinase in resistance of cancer cells to therapy. Drug Resist Updat (2003) 1.09
Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. J Clin Oncol (2003) 1.08
Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Res (2007) 1.08
Supervised multi-view canonical correlation analysis (sMVCCA): integrating histologic and proteomic features for predicting recurrent prostate cancer. IEEE Trans Med Imaging (2014) 1.07
Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. Clin Cancer Res (2013) 1.03
Macrophage migration inhibitory factor is a determinant of hypoxia-induced apoptosis in colon cancer cell lines. Clin Cancer Res (2005) 1.03
Graph embedding to improve supervised classification and novel class detection: application to prostate cancer. Med Image Comput Comput Assist Interv (2005) 1.03
Downregulation of Rap1GAP in human tumor cells alters cell/matrix and cell/cell adhesion. Mol Cell Biol (2010) 1.03
The antivascular action of physiotherapy ultrasound on murine tumors. Ultrasound Med Biol (2005) 1.02
Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor kappaB signaling. Cancer Res (2003) 1.02
Loss of Rap1GAP in papillary thyroid cancer. J Clin Endocrinol Metab (2008) 1.02
The terrible choice: re-evaluating hospice eligibility criteria for cancer. J Clin Oncol (2008) 0.98
Fibrillin and other matrix proteins in mitral valve prolapse syndrome. Ann Thorac Surg (2004) 0.97
Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. Biochem Pharmacol (2002) 0.97
17-Allylamino-17-demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell lines. Biochem Pharmacol (2005) 0.96
Fungal rhinosinusitis: a retrospective microbiologic and pathologic review of 400 patients at a single university medical center. Int J Otolaryngol (2012) 0.96
Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. Invest New Drugs (2009) 0.94
Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. Cancer (2011) 0.94
Signaling pathways in NSCLC as a predictor of outcome and response to therapy. Lung (2004) 0.93
Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol (2009) 0.93
Supervised regularized canonical correlation analysis: integrating histologic and proteomic measurements for predicting biochemical recurrence following prostate surgery. BMC Bioinformatics (2011) 0.93
Ectopic functioning adrenocortical oncocytic adenoma (oncocytoma) with myelolipoma causing virilization. Case Rep Pathol (2012) 0.92
Spatially weighted mutual information (SWMI) for registration of digitally reconstructed ex vivo whole mount histology and in vivo prostate MRI. Conf Proc IEEE Eng Med Biol Soc (2011) 0.91
Interleukin-12 inhibits angiogenesis and growth of transplanted but not in situ mouse mammary tumor virus-induced mammary carcinomas. Cancer Res (2002) 0.91
Dose-dependent effects of topical tobramycin in an animal model of Pseudomonas sinusitis. Am J Rhinol (2007) 0.90
NF-kappaB activation by the chemopreventive dithiolethione oltipraz is exerted through stimulation of MEKK3 signaling. J Biol Chem (2004) 0.90
Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction. Cancer Res (2003) 0.90
Radiographic and histologic analysis of the bone underlying inverted papillomas. Laryngoscope (2006) 0.90
High-throughput biomarker segmentation on ovarian cancer tissue microarrays via hierarchical normalized cuts. IEEE Trans Biomed Eng (2011) 0.89
Integration of architectural and cytologic driven image algorithms for prostate adenocarcinoma identification. Anal Cell Pathol (Amst) (2012) 0.89
Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors. Cancer Chemother Pharmacol (2005) 0.88
Computer aided automatic detection of malignant lesions in diffuse optical mammography. Med Phys (2010) 0.88
Strong signature of natural selection within an FHIT intron implicated in prostate cancer risk. PLoS One (2008) 0.87
Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines. Mol Pharmacol (2004) 0.87
Variability in the diagnosis of dysplasia in ulcerative colitis by dynamic telepathology. Oncol Rep (2006) 0.86
Role of the AP-1 element and redox factor-1 (Ref-1) in mediating transcriptional induction of DT-diaphorase gene expression by oltipraz: a target for chemoprevention. Biochem Pharmacol (2003) 0.85
Inhibition of G1/S transition potentiates oxaliplatin-induced cell death in colon cancer cell lines. Biochem Pharmacol (2007) 0.85
Optical malignancy parameters for monitoring progression of breast cancer neoadjuvant chemotherapy. Biomed Opt Express (2012) 0.85
Ras-related protein 1 and the insulin-like growth factor type I receptor are associated with risk of progression in patients diagnosed with carcinoma in situ. Breast Cancer Res Treat (2010) 0.84
Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol (2011) 0.84
The impact of HER-2 status on local recurrence in women with stage I-II breast cancer treated with breast-conserving therapy. Breast J (2006) 0.84
Hierarchical normalized cuts: unsupervised segmentation of vascular biomarkers from ovarian cancer tissue microarrays. Med Image Comput Comput Assist Interv (2009) 0.84
In situ hybridization for Coccidioides immitis 5.8S ribosomal RNA sequences in formalin-fixed, paraffin-embedded pulmonary specimens using a locked nucleic acid probe: a rapid means for identification in tissue sections. Diagn Mol Pathol (2010) 0.84
Image microarrays (IMA): Digital pathology's missing tool. J Pathol Inform (2011) 0.84
Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype. Biochem Pharmacol (2002) 0.83
Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days. Clin Cancer Res (2003) 0.83
Eccrine porocarcinoma of the nose: case report and review of world literature. Arch Otolaryngol Head Neck Surg (2006) 0.83
Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma. Cancer Biol Ther (2011) 0.82
How should we design supportive cancer care? The patient's perspective. J Clin Oncol (2008) 0.82
Monoclonal antibodies in the treatment of colorectal cancer. Eur J Cancer (2004) 0.82
MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib. AJR Am J Roentgenol (2013) 0.82
Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer. Clin Cancer Res (2002) 0.81
Do phase 1 patients have greater needs for palliative care compared with other cancer patients? Cancer (2009) 0.81
Accumulation of intrahepatic islet amyloid in a nonhuman primate transplant model. Endocrinology (2012) 0.81
In situ detection of aspergillus 18s ribosomal RNA Sequences using a terminally biotinylated locked nucleic acid (LNA) probe. Diagn Mol Pathol (2009) 0.81